U.S. patent application number 16/273565 was filed with the patent office on 2020-02-06 for gastric, cutaneous, or peritoneal delivery of frozen mist to induce therapeutic hyperthermia.
This patent application is currently assigned to Qool Therapeutics, Inc.. The applicant listed for this patent is Qool Therapeutics, Inc.. Invention is credited to Amir Belson.
Application Number | 20200038237 16/273565 |
Document ID | / |
Family ID | 47832529 |
Filed Date | 2020-02-06 |
![](/patent/app/20200038237/US20200038237A1-20200206-D00000.png)
![](/patent/app/20200038237/US20200038237A1-20200206-D00001.png)
![](/patent/app/20200038237/US20200038237A1-20200206-D00002.png)
![](/patent/app/20200038237/US20200038237A1-20200206-D00003.png)
![](/patent/app/20200038237/US20200038237A1-20200206-D00004.png)
![](/patent/app/20200038237/US20200038237A1-20200206-D00005.png)
![](/patent/app/20200038237/US20200038237A1-20200206-D00006.png)
United States Patent
Application |
20200038237 |
Kind Code |
A1 |
Belson; Amir |
February 6, 2020 |
GASTRIC, CUTANEOUS, OR PERITONEAL DELIVERY OF FROZEN MIST TO INDUCE
THERAPEUTIC HYPERTHERMIA
Abstract
Peritoneal heat exchange provides the benefit of extremely rapid
cooling of the patient's target organs such as the heart and brain
as well as facilitating global patient body temperature reduction
to therapeutically effective temperatures. The heat exchange medium
of the present invention is a chilled gaseous fluid suspension of
frozen ice particles.
Inventors: |
Belson; Amir; (Savyon,
IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Qool Therapeutics, Inc. |
Menlo Park |
CA |
US |
|
|
Assignee: |
Qool Therapeutics, Inc.
Menlo Park
CA
|
Family ID: |
47832529 |
Appl. No.: |
16/273565 |
Filed: |
February 12, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15212175 |
Jul 15, 2016 |
10238533 |
|
|
16273565 |
|
|
|
|
13603955 |
Sep 5, 2012 |
9414959 |
|
|
15212175 |
|
|
|
|
61531052 |
Sep 5, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61F 2007/126 20130101;
A61F 7/02 20130101; A61F 2007/0069 20130101; A61F 7/0085 20130101;
A61F 2007/0095 20130101; A61F 7/12 20130101; A61F 2007/0063
20130101; A61F 2007/0234 20130101 |
International
Class: |
A61F 7/12 20060101
A61F007/12; A61F 7/02 20060101 A61F007/02; A61F 7/00 20060101
A61F007/00 |
Claims
1. A system for cooling a patient, said system comprising: a
generator which produces a flowing gas stream having entrained
frozen solid particles therein; and means for directing the flowing
gas stream to a body surface which is not part of the patient's
respiratory system, wherein the solid particles are directly
exposed to the body surface melt to absorb body heat to cause at
least one of lowering and controlling the patient's body
temperature, wherein passing the flowing gas stream comprises
introducing the flowing gas stream through an inlet conduit in an
abdominal wall into a body cavity and simultaneously removing the
flowing gas stream from the body cavity through an outlet conduit
in the abdominal wall and wherein the inlet conduit is separate
from the outlet conduit and the conduits are introduced through
opposed locations on the abdominal wall.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/212,175, filed Jul. 15, 2016, which is a
divisional of U.S. patent application Ser. No. 13/603,955, filed
Sep. 5, 2012, now U.S. Pat. No. 9,414,959, which claims the benefit
of U.S. Provisional Application No. 61/531,052, filed Sep. 5, 2011,
which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] The present invention relates generally to apparatus and
methods for selective modification and control of a patient's body
temperature. More particularly, it relates to relatively
non-invasive and field operable systems and methods of lowering a
patient's body temperature by heat exchange within the patient's
peritoneum. Peritoneal heat exchange provides the benefit of
extremely rapid cooling of the patient's target organs such as the
heart and brain as well as facilitating global patient body
temperature reduction to therapeutically effective temperatures.
The heat exchange medium of the present invention is a chilled
gaseous fluid suspension of frozen ice particles.
Background of the Invention
[0003] Man is considered to be a tropical animal. Normal
functioning of the human animal requires a body temperature of
approximately 37 degrees Celsius (98.6 degrees Fahrenheit). The
body can self-compensate for small upward or downward variations in
temperature through the activation of a built-in thermoregulatory
system, controlled by temperature sensors in the skin. The response
to an upward variation in body temperature is the initiation of
perspiration, which moves moisture from body tissues to the body
surface. When the moisture reaches the surface it evaporates,
carrying with it a quantity of heat. The explanation for a person
becoming thirsty when exposed to a hot environment for a period of
time is that fluids lost due to perspiration must be replaced. The
response to a downward variation in body temperature is shivering,
which is the body's attempt to generate heat. Shivering is an
involuntary contraction and expansion of muscle tissue occurring on
a large scale. This muscle action creates heat through
friction.
[0004] Hypothermia is defined as a core temperature of less than 35
degrees Celsius. Hypothermia is also considered the clinical state
of subnormal temperature when the body is unable to generate
sufficient heat to effectively maintain functions. Many variables
contribute to the development of hypotherthermia. Age, health,
nutrition, body size, exhaustion, exposure, duration of exposure,
wind, temperature, wetness, medication and intoxicants may decrease
heat production, increase heat loss, or interfere with
thermostability. The healthy individual's compensatory responses to
heat loss via conduction, convection, radiation, evaporation and
respiration may be overwhelmed by exposure. Medications may
interfere with thermoregulation. Acute or chronic central nervous
system processes may decrease the effectiveness of
thermoregulation.
Mild Hypothermia is when the core temperature is 34-35 degrees
Celsius. The patient is still alert and able to help him/herself
and intense shivering begins. The patient's movements, however,
become less coordinated and the coldness creates some pain and
discomfort.
[0005] Moderate hypothermia is when the patient's core temperature
is 31-33 degrees Celsius. Shivering slows or stops, muscles begin
to stiffen and mental confusion and apathy sets in. Speech becomes
slow, vague and slurred, breathing becomes slow and shallow, and
drowsiness and strange behavior may occur.
[0006] Severe hypothermia is when the core temperature drops below
31 degrees Celsius. Skin is cold, may be bluish-gray in color, eyes
may be dilated. The patient is very weak, displays a marked lack of
coordination, slurred speech, appears exhausted, may appear to be
drunk, denies there is a problem and may resist help. There is a
gradual loss of consciousness. There may be little or no apparent
breathing, the patient may be very rigid, unconscious, and may
appear dead.
[0007] Simple methods for treating hypothermia have been known
since very early times. Such methods include wrapping the patient
in blankets, administering warm fluids by mouth, and immersing the
patient in a warm water bath. Even these simple methods may be
effective if the hypothermia is not too severe. These simple
methods are limited in their effectiveness however. Wrapping the
patient in blankets ultimately depends on the patient's own
production of heat to rewarm his body. In even moderate cases of
hypothermia, or in the case of an ill or injured patient, the
patient may simply be too weak or exhausted to produce sufficient
heat. Oral administration of a warm fluid requires that the patient
be conscious and capable of swallowing the fluid. Since loss of
consciousness occurs early in hypothermia, this method is also
limited to moderate cases Immersion of the patient in a warm water
bath is often simply impractical. For example, immersion of a
patient undergoing surgery would obviously be undesirable.
Furthermore, the immersion technique is time consuming and may be
ineffective in that it requires the transmission of warmth from the
patient's skin surface into the body core before the benefit of the
warmth can be realized. Other devices allow for the direct warming
of a patient's blood. These methods involve removing blood from the
patient, warming the blood in external warming equipment, and
delivering the blood back into the patient. While such methods are
much more effective than any of the simple methods previously
described, they are disadvantageous for other reasons. First, the
apparatus involved is quite cumbersome. Second, some danger is
involved in even the temporary removal of significant quantities of
blood from an already weakened patient. In fact, a further drop in
body temperature is often experienced when blood is first removed
for warming in the external apparatus. Finally, special catheters
are used for the direct warming of a patient's blood. However,
those catheters require a trained staff to insert the device to a
central blood vessel of the patient and those physicians are
available only in specific units and not in the ambulance or even
not always in the emergency room. Those instruments are also very
expensive and thus are not available for every caregiver.
[0008] Recent medical reports have described the use of controlled
hypothermia as a means to reduce oxygen consumption of tissue, such
as the heart muscle and the brain during decreased perfusion that
occurs as a result of myocardial infarction and ischemic stroke
(respectively), which leads to reduced damage and decrease of the
infarcted area. Medical reports have also described the
prophylactic use of controlled hypothermia during cardiac surgery
or interventional cardiology procedures for reducing damage from
ischemia and/or embolization in the heart and brain during and
after the procedure.
[0009] The ability to prevent or greatly reduce long term damage to
cardiac or brain tissue while treating patients for myocardial
infarction and stroke provides a compelling need for methods and
systems for purposefully inducing therapeutic hypothermia in
controlled effective manner. Such systems are ideally portable and
deployable by emergency medical responders in the field and must be
capable of rapidly cooling vital heart and brain tissues to prevent
as much damage as possible. As of yet an ideal system or method for
rapidly inducing hypothermia non-invasively and outside of a
critical care hospital setting does not exist. Cooling blankets
offer a portable easily deployable means of chilling a patient but
the body's own thermoregulatory mechanisms counteract the cooling
mechanisms of such blankets through vasoconstriction. As a result
cooling blankets are not able to induce hypothermia in the patient
in clinically relevant time span. Ice baths are capable of reducing
patient body temperature rapidly due to the large thermal gradient
and large specific heat capacity of the cooling medium. However ice
baths are not portable are inconsistent with necessary concurrent
interventions required for treatment of MI and stroke, such as
balloon angioplasty. Peritoneal catheters equipped with heat
exchangers are capable of rapid cooling of the patient but the size
required of such catheters makes their deployment invasive.
Additionally such catheterizations require skilled technicians and
must be performed in the hospital. By the time a patient has
reached a hospital much critical time has been lost. Field
deployable respiratory cooling systems that operate by using the
body's own lungs as heat exchangers and use a gaseous fluid
suspension of frozen particles as a convective cooling medium are
capable of inducing hypothermia in clinically relevant time spans.
However, often in medical emergencies such as stroke or MI the
patient exhibits poor or depressed respiration. Additionally,
respiratory cooling mechanisms have yet to match cooling rates of
peritoneal cooling.
[0010] The following patents and patent applications describe
apparatus and methods for affecting a patient's body temperature.
These, and all other patents and patent applications referred to
herein, are hereby incorporated by reference in their entirety.
Background Art
[0011] U.S. Pat. No. 8,100,123 and US2012/0167878 commonly assigned
with the present application describe method and systems for
delivering a frozen mist in a breathing gas to a patient to achieve
hypothermia. The full disclosures of these patent documents are
incorporated herein by reference.
[0012] WO03059425 Method for altering the body temperature of a
patient using a nebulized mist--Body temperature reducing method
involves administering nebulized mist at temperature below body
temperature of patient until patient's temperature 2 is
reduced.
[0013] US20030136402 Method for altering the body temperature of a
patient using a nebulized mist--Body temperature reducing method
involves administering nebulized mist at temperature below body
temperature of patient until patient's temperature is reduced.
[0014] U.S. Pat. No. 6,303,156 Noninvasive method for increasing or
decreasing the body temperature of a patient--Increasing or
decreasing body temperature for treating e.g. hemorrhagic shock
comprises administering oxygen and sulfur hexafluoride gas mixture
by hyperventilation.
[0015] EP1089743 Composition containing sulfur hexafluoride and
oxygen, for increasing or decreasing the body temperature of a
patient--Increasing or decreasing body temperature for treating
e.g. hemorrhagic shock comprises administering oxygen and sulfur
hexafluoride gas mixture by hyperventilation.
[0016] WO9966938 Composition containing sulfur hexafluoride and
oxygen, for increasing or decreasing the body temperature of a
patient--Increasing or decreasing body temperature for treating
e.g. hemorrhagic shock comprises administering oxygen and sulfur
hexafluoride gas mixture by hyperventilation.
[0017] US20030066304 Method for inducing hypothermia.
Hypothermia-inducing treatment method for patient in cardiac arrest
involves performing continuous administering of phase-change
particulate slurry to patient in cardiac arrest until state of
hypothermia is induced to patient.
[0018] U.S. Pat. No. 6,547,811 Method for inducing
hypothermia--Improvement of a cardiac arrest patient's outcome
by
pre-hospital administration of a phase-change particulate slurry
internally until a state of hypothermia is induced.
[0019] WO0108593 Method for inducing hypothermia--Improvement of a
cardiac arrest patient's outcome by pre-hospital administration of
a phase-change particulate slurry internally until a state of
hypothermia is induced.
[0020] US20030131844 Inducing hypothermia and rewarming using a
helium-oxygen mixture--Composition useful for treating ischemic
event by inducing hypothermia comprises a gas mixture comprising
helium and oxygen having temperature significantly different than
normal human body temperature.
[0021] WO03047603 Breathable gas mixtures to change body
temperature--Composition useful for treating ischemic event by
inducing hypothermia comprises a gas mixture comprising helium and
oxygen having temperature significantly different than normal human
body temperature.
SUMMARY OF THE INVENTION
[0022] The present invention provides methods and systems for the
improved cooling of a patient to selectively induce hypothermia.
The methods and systems rely on producing a flowing gas stream,
which carries an entrained mist or suspension of frozen solid
particles. The flowing gas stream is passed by or over a body
surface which is not part of the patient's respiratory system, and
at least some of the frozen mist particles will melt such that the
resulting phase change in absorbs large amounts of the body heat,
thus reducing the body temperature. The enthalpic heat absorption
resulting from the phase change from the frozen particles melting
(or in some cases, subliming) provides much greater heat absorption
than would be possible using a cooled gas stream by itself. Cooling
of body surfaces other than those in the respiratory system is also
advantageous in that many such surfaces can be easily accessed and
it is not necessary that the patient be breathing at the time of
the treatment.
[0023] In a first aspect of the present invention, a method for
cooling the patient comprises generating a mist of frozen solid
particles in a flowing gas stream. The flowing gas stream is passed
over a targeted body surface which is not part of the patient's
respiratory system. The solid particles melt or sublime to absorb
body heat to lower the patient's body temperature. The body surface
will often be part of a body cavity, typically being within a
patient's abdominal cavity or stomach. Alternatively, the body
surface may be an external surface, such as the skin over the
patient's torso.
[0024] When cooling a body cavity, the flowing gas stream is
typically passed through an abdominal wall and the gas stream
(which would otherwise accumulate within the body cavity) is also
removed through the abdominal wall. Typically, inlet and outlet
conduits are positioned through the abdominal wall, and the flowing
gas stream is introduced through the inlet conduit and removed
through the outlet conduit. Often, separate inlet and outlet
conduits will be used and introduced through opposed locations on
the abdominal wall in order to promote more complete circulation
within the body cavity. In other cases, the inlet and outlet
conduits may be combined in a single structure which is introduced
through a single penetration in the abdominal wall.
[0025] In an alternative embodiment, the patient's skin or torso is
exposed. The skin or torso will usually be covered with a jacket or
similar structure which covers at least a portion of the torso and
which constrains the flowing gas stream so that it effectively
cools the patient's skin. The jacket may be in the form of a
"bladder" or other sealed system, in which case the flowing gas
stream would recirculate within a sealed exterior and the transfer
would take place over a wall of the jacket. In other cases, the
jacket may be opened so that the flowing gas stream is allowed to
directly contact the skin for a more efficient heat transfer.
[0026] The mist of frozen particles is typically generated by
cooling the flowing gas stream and injecting liquid droplets into
the stream so that they freeze in situ. Cooling the gas may be
effected in conventional manners, often by expansion through an
expansion valve in order to cause adiabatic cooling. Optionally,
the droplets or liquid which is formed into the droplets may also
be cooled before they are injected into the flowing gas stream. The
liquid and gas may comprise any suitable, biocompatible fluids
which provide for significant enthalpic heat absorption where the
frozen particles will melt or sublime at body temperature. Most
commonly, the liquid will be water and the gas will be air,
nitrogen, heliox, HF.sub.6, carobon dioxide or another common gas.
In other instances, however, the gas particles could be frozen
carbon dioxide (dry ice) which would sublime when exposed to the
body surface in order to absorb heat. Dry ice could optionally be
provided as a solid mass, where the mass is broken down into small
particles which can be injected into a flowing gas stream
(therefore the gas stream need not be cooled or as cooled).
[0027] In a further aspect of the present invention, the system for
cooling a patient comprises a generator which produces a mist of
frozen particles in a flowing gas stream. The system further
comprises a mechanism for directing the flowing gas stream to a
body surface which is not part of a patient's respiratory system.
Optionally, the frozen mist generator may be created without
freezing a liquid in a chilled gas stream. Rather the frozen
particle mist is created in a separate production apparatus such as
a nebulizer or ice fog machine. An ice fog machine is typically
capable of chilling a solution of air with high humidity below the
freezing point of water. Small ice crystals nucleate to form a
suspension of frozen particle mist of small ice particles. The
frozen particle mist may then be further mixed with a chilled
gaseous fluid stream an un-chilled gaseous fluid stream or used on
its own.
[0028] The generator may comprise a chiller for cooling the gas, a
pump for producing the flowing gas stream, and a nozzle for
injecting a liquid into the cooled, flowing gas stream. The
directing means comprise of a tubular member for penetrating an
abdominal wall to introduce the flowing gas stream to an abdominal
cavity or stomach. Alternately, first and second tubular elements
will be employed for both introducing a gas stream and for removing
the gas stream from the cavity. Alternatively, the directing means
can comprise a jacket for placing over the patient to direct a flow
over the patient's torso.
INCORPORATION BY REFERENCE
[0029] All publications and patent applications mentioned in this
specification are herein incorporated by reference to the same
extent as if each individual publication or patent application was
specifically and individually indicated to be incorporated by
reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The novel features of the invention are set forth with
particularity in the appended claims. A better understanding of the
features and advantages of the present invention will be obtained
by reference to the following detailed description that sets forth
illustrative embodiments, in which the principles of the invention
are utilized, and the accompanying drawings of which:
[0031] FIG. 1 shows a system that creates frozen mist through fluid
spray injection into a cold gas flow.
[0032] FIG. 2 shows a system a gastric tube that has two channels.
One that enables inflow and the second enables outflow.
[0033] FIG. 3 shows the peritoneal mist delivery system with at
least two needles.
[0034] FIG. 4 shows the peritoneal mist delivery system with at
least two catheters.
[0035] FIG. 5 shows the turbulence that may create the desired wind
chill effect in the peritoneum.
[0036] FIG. 6 illustrates a suit which covers the skin with a space
for frozen mist (with or without turbulence) delivered to the skin
under the suit.
DETAILED DESCRIPTION OF THE INVENTION
[0037] The basis of operation for the invention described in the
following embodiments is the circulation of a chilled gaseous fluid
throughout the abdominal cavity wherein the chilled fluid has a
suspension or mist of frozen particles. Typically a chilled gaseous
fluid is produced using a chilled fluid source which may comprise a
vessel storing a gas in a compressed state and/or refrigerated
state. Adiabatic expansion of the gas results in a moving stream of
further chilled gas, The gas typically comprises air, HELIOX (a
mixture of 20% O.sub.2 and 80% He.sub.2), or sulfur hexafluoride
(HF.sub.6) but may further comprise any biocompatible gas with
specific heat capacity sufficient enough for cooling operations.
The chilled gaseous fluid may alternatively be produce by an
suitable refrigeration system, such electrically powered
refrigerators, gas or propane powered refrigerators, or any
suitable gas refrigeration's system known in the art. The frozen
particles typically comprise ice and are produced by the
introduction of a spray of a second fluid, typically liquid water,
from a fluid source into the stream of the chilled gas. The cooling
gas, having been chilled to below the freezing temperature of water
freezes the water droplets. Although the particles typically
comprise ice it should be appreciated that any biocompatible fluid
with an appropriate freezing point, heat capacity and enthalpy of
fusion may be used instead of liquid water. The suspension of
frozen particles (mist) acts to augment the cooling properties of
the gas/ice mixture. The latent heat required to overcome the
enthalpy of fusion to melt the ice particles ensures that the
cooling media temperature remains close to 0.degree. C. and the
preservation of the thermal gradient across the tissue media
interface. Removing heat from the patient rapidly requires
maintaining a large temperature gradient between the tissues being
cooled and the cooling media. Additionally, the phase change
required to melt the frozen particle mist increases the total
amount of energy the chilled fluid and mist mixture can remove from
the patient. The total power removed from system is proportional to
the rate of addition of ice particles as shown by the calculations
in Table 1 shown below.
TABLE-US-00001 TABLE 1 Power to Heat Ice Power for Solid/ Power to
Heat Liquid Rate of Ice Particle from -30.degree. C. to Liquid
Phase from 0.degree. C to Total Addition (liter/hour) 0.degree. C.
(W) Change (W) 37.degree. C. (W) Power (W) 0.25 3.8 21.5 10.0 35.2
0.5 7.5 42.9 19.9 70.4 1 15.1 85.9 39.8 140.8 2.5 37.7 214.7 99.6
352.1 5 75.4 429.5 199.2 704.1
The calculations assume that the ice is mixed with air at
atmospheric pressure; the air ice mixture is initially at
-30.degree. C. with a volumetric flow rate of 20 l/min.
[0038] One exemplary embodiment of the present invention is shown
in FIG. 1. A main conduit 110 is shown in a patient penetrating the
patient's abdominal wall AW in order to distribute a mixture of
chilled gas and frozen mist into the abdominal cavity. A distal end
112 of the main conduit 110 located in a peritoneum P. A chilled
fluid source 101 is connected to a main lumen 113 of the main
conduit 110. A fluid port 114 allows for the introduction of a
liquid from a second fluid source 102. The fluid port 114 is show
proximal to the abdominal wall however it should be appreciated
that the fluid port 114 may be located distal to the abdominal
wall. The fluid injection port 114 may be adapted to atomize the
liquid, such that a mist of small liquid droplets forms as the
fluid is introduced into the chilled gas flow. The small droplets
freeze as they exchange thermal energy with the chilled gaseous
fluid stream 103 to form a frozen particle suspension (a mist) 104.
The mixture 105 of chilled gaseous fluid 103 and frozen particle
mist 104 exits the main conduit 110 into the abdominal cavity to
chill tissues therein. A sensor package 106 may be used to monitor
at least one of the following: patient body temperature, abdominal
cavity body temperature, target organ temperature, chilled gaseous
fluid flow rate, or liquid fluid introduction rate. Data measured
by sensor package 106 is used may be used by a processor/controller
107 to modify the production and flow rate of the mixture 105, the
flow and temperature of the gaseous fluid stream 103 in order to
control the patient's temperature two within targeted therapeutic
ranges. It should be understood that the fluid stream 103 and
mixture 105 may not always be introduced into the patient's
abdominal cavity in a continuous fashion. If the
processor/controller 107 receives data from the sensor package 106
that indicates the temperature of patient's tissues are falling
below the designated therapeutic range into potentially harmful
ranges then the processor/controller may alter the characteristics
of the gaseous fluid stream 103 or the mixture 105 or stop or
retard the flow of either the gaseous fluid stream and/or the
mixture 105.
[0039] Another embodiment of the invention is shown in FIG. 2. A
main conduit 210 is shown in a patient penetrating the patient's
abdominal wall AW and placed into the patient's peritoneum P. The
main conduit 210 comprises an inflow lumen 211 and an outflow lumen
212. The inflow lumen 211 is connected to a chilled gaseous fluid
source 201. A stream of chilled gaseous fluid 203 flows through the
inflow lumen 211 where it encounters a spray of liquid, typically
water, introduced by the a liquid source 202 at a fluid injection
port 214. The spray of liquid is frozen by the chilled gaseous
fluid stream into a mist 204 of small frozen particles (typically
ice). The mixture 205 of chilled gaseous fluid 203 and mist 204
proceeds from the inflow lumen 211 into the abdominal cavity of the
patient to cool the patient. Thermal energy is removed from the
patient as the mixture 205 is heated and the frozen particles of
mist 204 melt. To facilitate further cooling the mixture 205 may be
extracted out of the abdominal cavity through outflow lumen 212,
which is optionally connected to a vacuum source 208. Evacuation of
mixture 205 from the abdominal cavity may be accomplished via the
vacuum source 208 or via passive means relying on positive pressure
created in the abdominal cavity. The extraction of mixture 205 from
the abdominal cavity ensures that more of mixture 205 can continue
to flow through inflow lumen 211 and that the mixture 205 remains
sufficiently cold relative to the patient to ensure continual rapid
cooling of the patient. Inflow conduit 211 and outflow conduit 212
each have independent valves 221 and 222 respectively. This allows
introduction of the mixture 205 and extraction of the mixture 205
to occur independently or simultaneously. Inflow lumen 211 and
outflow lumen 212 may have different lengths, such that mixture 205
is introduced into the abdominal in a different location than
mixture 205 is removed from the abdominal cavity. This may be done
in an effort to prevent shunting and to better distribute the
mixture 205 throughout the abdominal cavity. A sensor package 206
may be used to monitor at least one of the following: patient body
temperature, abdominal cavity body temperature, target organ
temperature, chilled gaseous fluid flow rate, or liquid fluid
introduction rate. A processor/controller 207 is connected to the
chilled gaseous fluid source 201, liquid source 202, and sensor
package 206, and vacuum source 208 and is capable of controlling
the functioning of any of these elements. Data measured by sensor
package 206 is used may be used by a processor/controller 207 to
modify the production and flow rate of the mixture 205, the amount
of frozen particle mist in mixture 205, and the extraction rate of
mist 205 from the abdominal cavity, and actuation of valving 221
and 222 in order to control the patient's temperature to within
targeted therapeutic ranges. It should be understood that
processor/controller 207 is able to independently modify the flow
rate of chilled gaseous fluid 202, rate of mist 204 generation and
flow rate of mixture 205, as well as extraction rate of mixture 205
from the abdominal cavity. At any point, the flow of chilled
gaseous fluid 202, generation of mist 204 and flow mixture 205 into
the abdominal cavity and extraction of the mixture 205 from the
abdominal cavity may be independently stopped by the
processor/controller 207.
[0040] Another embodiment of the invention is shown in FIG. 3. Two
needles are shown in a patient, an inflow needle 311 and an outflow
needle 312. The inflow needle 311 and outflow needle 312 are shown
inserted into the patient's abdominal cavity penetrating the
patient's abdominal wall AW their respective ends in the peritoneum
P. Typically the inflow needle 311 and outflow needle 312 are
veress needles designed to reach the peritoneum without damaging
internal organs IO. However, any safety needle or surgical access
needle suitable for such use known to the art may be used. The
inflow needle is connected to a chilled gaseous fluid source 301
which produces a stream of chilled gas 303. A Fluid injection port
314 in the inflow needle 311 connects the inflow needle 311 to a
liquid fluid source 302 and produces a spray of liquid which
freezes into a mist 304 of frozen particles to produce a mixture
305 of chilled gaseous fluid and frozen particle mist. The mixture
305 then exits the inflow needle into the abdominal cavity,
typically in the peritoneum P. The mixture 305 is shown flowing
over internal organs IO extracting heat 350 from said internal
organs IO, it is understood that heat is also extracted from all
tissues in the abdominal cavity that come in contact with the
mixture 305. In the process of removing heat from a patient's
internal organs the mixture 305 will become heated and frozen
particles in the mist 304 melt. To ensure continual rapid heat
extraction from the patient, the mixture 305 is extracted from the
abdominal cavity through the outflow needle 312, which is
optionally connected to a vacuum source 308. Vacuum source 308 may
be used to aid in extraction of the mixture 305, alternatively
passive extraction relying on positive partial pressure in the
abdominal cavity may be used instead. Inflow needle 311 and outflow
needle 312 are each equipped with independent valves 321 and 322
respectively to aid in controlling the flowrate and extraction rate
of mixture 305. A sensor package 306 may be used to monitor at
least one of the following: patient body temperature, abdominal
cavity body temperature, target organ temperature, chilled gaseous
fluid flow rate, or liquid fluid introduction rate A
processor/controller 307 is connected to the chilled gaseous fluid
source 301, liquid source 302, and sensor package 306, and vacuum
source 308 and is capable of controlling the functioning of any of
these elements. Data measured by sensor package 306 is used may be
used by a processor/controller 307 to modify the production and
flow rate of the mixture 305, the amount of frozen particle mist in
mixture 305, and the extraction rate of mist 305 from the abdominal
cavity, and actuation of valving 321 and 322 in order to control
the patient's temperature to within targeted therapeutic ranges. It
should be understood that processor/controller 307 is able to
independently modify the flow rate of chilled gaseous fluid 302,
rate of mist 304 generation and flow rate of mixture 305, as well
as extraction rate of mixture 305 from the abdominal cavity. At any
point, the flow of chilled gaseous fluid 302, generation of mist
304 and flow mixture 305 into the abdominal cavity and extraction
of the mixture 305 from the abdominal cavity may be independently
stopped or restarted by the processor/controller 307.
[0041] Another embodiment of the invention is shown in FIG. 4. Two
catheters are shown in a patient's abdominal cavity an inflow
catheter 411 and an outflow catheter 412. The inflow catheter 411
and outflow catheter 412 are shown inserted into the abdominal
cavity penetrating the abdominal wall AW their respective ends in
the peritoneum P. The inflow catheter and outflow catheter may
optionally be inserted over veress needles. The inflow needle is
connected to a chilled gaseous fluid source 401 which produces a
stream of chilled gas 403. A Fluid injection port 414 in the inflow
catheter 411 connects the inflow catheter 411 to a liquid fluid
source 402 and produces a spray of liquid which freezes into a mist
404 of frozen particles to produce a mixture 405 of chilled gaseous
fluid and frozen particle mist. The mixture 405 then exits the
inflow catheter into the abdominal cavity, typically in the
peritoneum P. The mixture 405 is shown flowing over internal organs
IO extracting heat 450 from said internal organs IO, it is
understood that heat is also extracted from all tissues in the
abdominal cavity that come in contact with the mixture 405. In the
process of removing heat from a patient's internal organs the
mixture 405 will become heated and frozen particles in the mist 404
melt. To ensure continual rapid heat extraction from the patient,
the mixture 405 is extracted from the abdominal cavity through the
outflow catheter 412, which is optionally connected to a vacuum
source 408. Vacuum source 408 may be used to aid in extraction of
the mixture 405, alternatively passive extraction relying on
positive partial pressure in the abdominal cavity may be used
instead. Inflow catheter 411 and outflow catheter 412 are each
equipped with independent valves 421 and 422 respectively to aid in
controlling the flowrate and extraction rate of mixture 405. A
sensor package 406 may be used to monitor at least one of the
following: patient body temperature, abdominal cavity body
temperature, target organ temperature, chilled gaseous fluid flow
rate, or liquid fluid introduction rate. A processor/controller 407
is connected to the chilled gaseous fluid source 401, liquid source
402, and sensor package 406, and vacuum source 408 and is capable
of controlling the functioning of any of these elements. Data
measured by sensor package 406 is used may be used by a
processor/controller 407 to modify the production and flow rate of
the mixture 405, the amount of frozen particle mist in mixture 405,
and the extraction rate of mist 405 from the abdominal cavity, and
actuation of valves 421 and 422 in order to control the patient's
temperature to within targeted therapeutic ranges. It should be
understood that processor/controller 407 is able to independently
modify the flow rate of chilled gaseous fluid 402, rate of mist 404
generation and flow rate of mixture 405, as well as extraction rate
of mixture 305 from the abdominal cavity. At any point, the flow of
chilled gaseous fluid 402, generation of mist 304 and flow mixture
405 into the abdominal cavity and extraction of the mixture 405
from the abdominal cavity may be independently stopped or restarted
by the processor/controller 407.
[0042] Another embodiment of the invention is shown in FIG. 5. Two
catheters are shown an inflow conduit 511 and an outflow conduit
512. The inflow conduit 411 and outflow conduit 412 are shown
inserted into a patient's abdominal cavity penetrating the
abdominal wall AW, their respective ends in the peritoneum P. The
inflow conduit 511 and outflow conduit 512 may each be either a
needle or catheter. The inflow conduit is connected to a chilled
gaseous fluid source 501 which produces a stream of chilled gas
503. A Fluid injection port 514 in the inflow conduit 511 connects
the inflow catheter 511 to a liquid fluid source 502 and produces a
spray of liquid which freezes into a mist 504 of frozen particles
to produce a mixture 505 of chilled gaseous fluid and frozen
particle mist. The mixture 505 then exits the inflow catheter into
the abdominal cavity, typically in the peritoneum P. The mixture
505 is shown flowing over internal organs IO extracting heat 550
from said internal organs IO, it is understood that heat is also
extracted from all tissues in the abdominal cavity that come in
contact with the mixture 505. In the process of removing heat from
a patient's internal organs the mixture 505 will become heated and
frozen particles in the mist 504 melt. To ensure continual rapid
heat extraction from the patient, the mixture 505 is extracted from
the abdominal cavity through the outflow catheter 512, which is
optionally connected to a vacuum source 508. Vacuum source 508 may
be used to aid in extraction of the mixture 505, alternatively
passive extraction relying on positive partial pressure in the
abdominal cavity may be used instead. Inflow conduit 511 and
outflow conduit 512 are each equipped with independent valves 521
and 522 respectively to aid in controlling the flowrate and
extraction rate of mixture 505. In this embodiment a turbulent flow
520 of mixture 505 is created in the abdominal cavity. The
turbulent flow enhances the rate of heat transfer in the peritoneum
by ensuring that the fluid layer of mixture 505 contacting the
internal organs IO is well mixed with the rest of the mixture 505
present in the abdominal cavity. This helps to maintain a large
thermal gradient between the mixture 505 and the internal organs IO
ensuring maximal heat flow. The turbulent flow may be generated by
means well known in the art such as modified tips for conduits 511
and 512 or by controlling the physical arrangement of conduits 511
and 512 in the abdominal cavity along with the flow rate and the
pressure of mixture 505 entering and exiting the abdominal cavity
through conduits 511 and 512 respectively. A sensor package 506 may
be used to monitor at least one of the following: patient body
temperature, abdominal cavity body temperature, target organ
temperature, chilled gaseous fluid flow rate, or liquid fluid
introduction rate. A processor/controller 507 is connected to the
chilled gaseous fluid source 501, liquid source 502, and sensor
package 506, and vacuum source 508 and is capable of controlling
the functioning of any of these elements. Data measured by sensor
package 506 is used may be used by a processor/controller 507 to
modify the production and flow rate of the mixture 505, the amount
of frozen particle mist in mixture 505, and the extraction rate of
mist 505 from the abdominal cavity, and actuation of valving 521
and/522 in order to control the patient's temperature to within
targeted therapeutic ranges. It should be understood that
processor/controller 507 is able to independently modify the flow
rate of chilled gaseous fluid 502, rate of mist 504 generation and
flow rate of mixture 505, as well as extraction rate of mixture 505
from the abdominal cavity. At any point, the flow of chilled
gaseous fluid 502, generation of mist 504 and flow mixture 505 into
the abdominal cavity and extraction of the mixture 505 from the
abdominal cavity may be independently stopped or restarted by the
processor/controller 507.
[0043] In an alternative embodiment, depicted in FIG. 6, a suit 630
is shown. The suit has tightening zones 631 around the neck, belly
and arms to create a substantial seal against the skin of a
patient's torso. The suit has at least one inflow port 611,
(multiple inflow ports shown) connected to a chilled gaseous fluid
source 601 and at least one outflow port 612 (multiple outflow
ports shown) connected to a vacuum source 608. A fluid liquid
source 602 provides a liquid fluid spray that frozen into a frozen
particle mist 604 in a stream if a chilled gaseous fluid 603 from
the chilled gaseous fluid source 601 to create mixture 605 of
chilled gaseous fluid 603 and frozen particle mist 604. The mixture
605 is directed through the inflow port(s) to the skin of the
patients torso. The mixture 605 then conducts heat transfer across
the patients torso, arms and neck removing heat from the patient
through the skin to induce a state of hypothermia. The mixture 605
is removed via the at outflow port(s) 612 which are connected to a
vacuum source 608. A sensor package 606 may be used to monitor at
least one of the following: patient body temperature, target organ
temperature, chilled gaseous fluid flow rate, or liquid fluid
introduction rate. Data measured by sensor package 606 is used may
be used by a processor/controller 607 to modify the production and
flow rate of the mixture 605, the amount of frozen particle mist in
mixture 605, and the extraction rate of mist 605 from the suit in
order to control the patient's temperature to within targeted
therapeutic ranges. At any point, the flow of mixture 605 into the
suit and extraction of the mixture 605 from the suit may be
independently stopped or restarted by the processor/controller
607.
[0044] In the embodiments shown in FIGS. 1-6 the liquid provided by
the various liquid sources is typically water and the mist
described in these embodiments is typically a suspension of ice
particles. It should be understood that the scope of the invention
is not limited to the use of liquid water. Any biocompatible frozen
mist suitable for cooling purposes may be used. For instance a
froze mist of dry ice may be produced by introducing finely milled
dry ice particles into a chilled gas stream in order to produce the
chilled fluid frozen mist mixtures described in the above
embodiments.
[0045] In the embodiments shown in FIGS. 1-5, the frozen mist
comprising the flowing gas stream and the frozen solid particles
entrained therein may be introduced into and/or extracted from a
patient's abdominal cavity (typically peritoneumor the stomach)
using conventional surgical access needles or catheters, such as
safety needles (e.g. veress needles), endogastric tubes, and the
like.
[0046] While preferred embodiments of the present invention have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. Numerous variations, changes, and substitutions will
now occur to those skilled in the art without departing from the
invention. It should be understood that various alternatives to the
embodiments of the invention described herein may be employed in
practicing the invention. It is intended that the following claims
define the scope of the invention and that methods and structures
within the scope of these claims and their equivalents be covered
thereby.
* * * * *